Researchers have shown that boosting levels of oestrogen in the brains of mice improved symptoms by slowing the build-up of the toxic protein alpha-synuclein. 

The Critical Path for Parkinson's meeting brought together pharmaceutical companies, universities, charities and regulatory bodies to address barriers to new treatments.

We’re investing £100,000 to improve compounds that have the potential to boost the function of brain cell batteries and slow the progression of Parkinson’s.

We're investing £1.5 million over 5 years in our Brain Bank, powering new research to understand more about Parkinson's.

Researchers have shown that an ‘easy to use’ portable stimulation headset may be able to reduce both motor and non-motor symptoms of Parkinson’s.

A new study published in Nature has shown that a gut infection can lead to symptoms resembling Parkinson's in mice, suggesting that the immune system may play a more central role in the condition than previously thought. 

We’re investing nearly £1 million to find a new treatment that targets energy-producing mitochondria to slow the loss of brain cells in Parkinson's.

In a seminal research paper, published in Lancet Neurology, researchers from King’s College London have used brain scans to uncover early changes in the brain that may happen years before the symptoms of Parkinson's appear.

Researchers in the US have identified a protein in the brain that may reduce the spread of the toxic alpha-synuclein protein in Parkinson's.

New research from Harvard University suggests changes to the gut could improve how a common Parkinson’s medication works.